MedPath

Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation

Phase 4
Completed
Conditions
Sick Sinus Syndrome
Registration Number
NCT00161538
Lead Sponsor
Medtronic BRC
Brief Summary

The purpose of this study is to determine which of 4 lead positions is most effective for pacemaker patients with Sick Sinus Syndrome in order to avoid development of atrial fibrillation.

Detailed Description

The incidence of Atrial Fibrillation (AF) in Sick Sinus Syndrome patients treated with pacing is quite high. As AF can cause dizziness, fatigue, thromboembolism and ischemic stroke it is clinically relevant. Due to earlier publications pacing modes and lead placement seem to influence the incidence of AF. In this study the incidence of AF will be compared between 4 different atrial lead positions:

1. Free atrial wall

2. right atrial appendage

3. coronary sinus-os

4. Dual site right atrial pacing: b) plus c).

The following primary parameters will be evaluated during the study period of 2 years after implantation:

1. Amounts of AF episodes with a duration of \> 48 hours

2. Amounts of AF episodes with a duration of \> 30 minutes

3. Consultations of physicians due to AF Secondarily, AF burden, Incidence of AF in total, Quality of Life, implant duration and complications will be evaluated.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
456
Inclusion Criteria
  • Sick Sinus Syndrome
  • Symptomatic sinus bradycardia
  • Symptomatic SA block
  • Bradycardia-Tachycardia-Syndrom
  • Binodal diseases, Sinus Node Syndrome and high degree AV-Block
  • In case of antiarrhythmic drug therapy: patient must be on a stable dose for at least 3 months before enrollment
Exclusion Criteria
  • Permanent atrial tachycardia that cannot be transferred into sinus rhythm by drugs or electric cardioversion
  • Decompensated heart failure
  • Dilatative cardiomyopathy with an ejection fraction < 35%
  • Hypertrophic obstructive cardiomyopathy
  • Symptomatic hypo- or hyperthyreosis
  • Myocardial infarction less than 6 months ago
  • Planned cardiac surgery intervention
  • Pregnant woman
  • Patients under 18 years of age
  • Patients involved in other studies
  • Patients, already implanted with other (cardiac) leads
  • Patients with reduced expectancy of life due to other diseases
  • Patients who are not able to agree in participation of the study
  • Patients, who cannot attend follow-up visits due to their place of residence

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The incidence of AF is determined via memory of the pacemaker, which is saved at every follow-up visit at 1 and 10 days after implant and further on at 3, 6, 12, 18 and 24 months after implant.
24-Hour ECG and treadmill exercise as well as echocardiography shall be performed before implant and 6, 12 and 24 months after implant
Secondary Outcome Measures
NameTimeMethod
Treadmill exercise test as well as echocardiography shall be performed before implant and 6, 12 and 24 month after implant.
Quality of Life questionnaires are obtained before implant and 12 and 24 months after implants

Trial Locations

Locations (12)

Klinikum Ingolstadt

🇩🇪

Ingolstadt, Germany

Universitätskrankenhaus Eppendorf

🇩🇪

Hamburg, Germany

Evangelisches Krankenhaus Kalk GmbH

🇩🇪

Köhl, Germany

Helios-Klinikum Aue

🇩🇪

Aue, Germany

Klinikum Coburg

🇩🇪

Coburg, Germany

Städtisches Krankenhaus Friedrichshafen

🇩🇪

Friedrichshafen, Germany

Klinikum der Joh.-Wolfgang-Goethe-Universität

🇩🇪

Frankfurt, Germany

Werner-Forssmann-Krankenhaus GmbH

🇩🇪

Eberswalde, Germany

Kreiskrankenhaus Leer

🇩🇪

Leer, Germany

Krankenhaus Maria Hilf

🇩🇪

Mönchengladbach, Germany

Ambulantes Herz-Zentrum Dresden

🇩🇪

Dresden, Germany

Evang. Krankenhaus

🇩🇪

Holzminden, Germany

© Copyright 2025. All Rights Reserved by MedPath